TY - JOUR
T1 - Dietary fat and obesity as modulators of breast cancer risk
T2 - Focus on DNA methylation
AU - Donovan, Micah G.
AU - Wren, Spencer N.
AU - Cenker, Mikia
AU - Selmin, Ornella I.
AU - Romagnolo, Donato F.
N1 - Funding Information:
This work was supported by the Arizona Cancer Center Support Grant P30CA23074 and a predoctoral training grant to M.G.D. from the Cancer Biology Training Grant T32CA009213.
Publisher Copyright:
© 2019 The British Pharmacological Society
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Breast cancer (BC) is the most common cancer and second leading cause of cancer mortality in women worldwide. Validated biomarkers enhance efforts for early detection and treatment, which reduce the risk of mortality. Epigenetic signatures have been suggested as good biomarkers for early detection, prognosis and targeted therapy of BC. Here, we highlight studies documenting the modifying effects of dietary fatty acids and obesity on BC biomarkers associated with DNA methylation. We focus our analysis on changes elicited in writers of DNA methylation (i.e., DNA methyltransferases), global DNA methylation and gene-specific DNA methylation. To provide context, we precede this discussion with a review of the available evidence for an association between BC incidence and both dietary fat consumption and obesity. We also include a review of well-vetted BC biomarkers related to cytosine-guanine dinucleotides methylation and how they influence BC risk, prognosis, tumour characteristics and response to treatment. Linked Articles: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc.
AB - Breast cancer (BC) is the most common cancer and second leading cause of cancer mortality in women worldwide. Validated biomarkers enhance efforts for early detection and treatment, which reduce the risk of mortality. Epigenetic signatures have been suggested as good biomarkers for early detection, prognosis and targeted therapy of BC. Here, we highlight studies documenting the modifying effects of dietary fatty acids and obesity on BC biomarkers associated with DNA methylation. We focus our analysis on changes elicited in writers of DNA methylation (i.e., DNA methyltransferases), global DNA methylation and gene-specific DNA methylation. To provide context, we precede this discussion with a review of the available evidence for an association between BC incidence and both dietary fat consumption and obesity. We also include a review of well-vetted BC biomarkers related to cytosine-guanine dinucleotides methylation and how they influence BC risk, prognosis, tumour characteristics and response to treatment. Linked Articles: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc.
UR - http://www.scopus.com/inward/record.url?scp=85078731760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078731760&partnerID=8YFLogxK
U2 - 10.1111/bph.14891
DO - 10.1111/bph.14891
M3 - Review article
C2 - 31691272
AN - SCOPUS:85078731760
SN - 0007-1188
VL - 177
SP - 1331
EP - 1350
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 6
ER -